Elna van der Ryst

Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

Roy M. Gulick, Jacob Lalezari, James Goodrich et al. · New England Journal of Medicine · 2008 · 741 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1

Gerd Fätkenheuer, Anton Pozniak, Margaret Johnson et al. · Nature Medicine · 2005 · 491 citations

Pharmacy, Pharmacology, Pharmacotherapy +14

Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection

Gerd Fätkenheuer, Mark Nelson, Adriano Lazzarin et al. · New England Journal of Medicine · 2008 · 361 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Emergence of CXCR4-Using Human Immunodeficiency Virus Type 1 (HIV-1) Variants in a Minority of HIV-1-Infected Patients following Treatment with the CCR5 Antagonist Maraviroc Is from a Pretreatment CXCR4-Using Virus Reservoir

Mike Westby, Marilyn Lewis, Jeannette M. Whitcomb et al. · Journal of Virology · 2006 · 331 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Maraviroc versus Efavirenz, Both in Combination with Zidovudine‐Lamivudine, for the Treatment of Antiretroviral‐Naive Subjects with CCR5‐Tropic HIV‐1 Infection

David A. Cooper, Jayvant Heera, James Goodrich et al. · The Journal of Infectious Diseases · 2010 · 265 citations

Pharmacy, Pharmacology, Pharmacotherapy +15